TP53 deletion is not an adverse feature in multiple myeloma treated with total therapy 3

British Journal of Haematology

Volumn 147, Issue 3, 2009, Pages 347-351

  Shaughnessy, John D ^a   Zhou, Yiming ^a   Haessler, Jeff ^b   Van Rhee, Frits ^a   Anaissie, Elias ^a   Nair, Bijay ^a   Waheed, Sarah ^a   Alsayed, Yazan ^a   Epstein, Joshua ^a   Crowley, John ^b   Barlogie, Bart ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Bortezomib; Genomics; Myeloma; Prognosis; TP53

Indexed keywords

BETA 2 MICROGLOBULIN; BORTEZOMIB; FIBROBLAST GROWTH FACTOR RECEPTOR 3; LACTATE DEHYDROGENASE; THALIDOMIDE;

ARTICLE; CHROMOSOME TRANSLOCATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; EVENT FREE SURVIVAL; FOLLOW UP; GENE DELETION; GENE EXPRESSION PROFILING; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SUPPRESSOR GENE; TP53 GENE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BORONIC ACIDS; FOLLOW-UP STUDIES; GENE DELETION; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; PYRAZINES; SURVIVAL ANALYSIS; TREATMENT OUTCOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70350001654     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07864.x     Document Type: Article

References (12)

1. Avet-Loiseau, H., Andree-Ashley, L.E., Moore, II., D., Mellerin, M.P., Feusner, J., Bataille, R. Pallavicini, M.G. (1997) Molecular cytogenetic abnormalities in multiple myeloma and plasma cell leukemia measured using comparative genomic hybridization. Genes, Chromosomes and Cancer, 19, 124 133.
2. Barlogie, B., Shaughnessy, J., Tricot, G., Jacobson, J., Zangari, M., Anaissie, E., Walker, R. Crowley, J. (2004) Treatment of multiple myeloma. Blood, 103, 20 32.
3. Barlogie, B., Tricot, G., Anaissie, E., Shaughnessy, J., Rasmussen, E., van Rhee, F., Fassas, A., Zangari, M., Hollmig, K., Pineda-Roman, M., Lee, C., Talamo, G., Thertulien, R., Kiwan, E., Krishna, S., Fox, M. Crowley, J. (2006) Thalidomide and hematopoietic-cell transplantation for multiple myeloma. New England Joural of Medicine, 354, 1021 1030.
4. Fonseca, R., Barlogie, B., Bataille, R., Bastard, C., Bergsagel, P.L., Chesi, M., Davies, F.E., Drach, J., Greipp, P.R., Kirsch, I.R., Kuehl, W.M., Hernandez, J.M., Minvielle, S., Pilarki, L.M., Shaughnessy, J.D., Stewart, A.K. Avet-Loiseau, H. (2004) Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Research, 64, 1546 1548.
5. Jacquemont, C. Taniguchi, T. (2007) Proteasome function is required for DNA damage response and fanconi anemia pathway activation. Cancer Research, 67, 7395 7405.
6. Mitsiades, N., Mitsiades, C.S., Richardson, P.G., Tai, Y.T., Chauhan, D., Fanourakis, G., Gu, X., Bailey, C., Joseph, M., Libermann, T.A., Schlossman, R., Munshi, N., Hideshima, T. Anderson, K. (2003) The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic implications. Blood, 101, 2377 2380.
7. Pineda-Roman, M., Zangari, M., Haessler, J., Anaissie, E., Tricot, G., van Rhee, F., Crowley, J., Shaughnessy, Jr., J.D. Barlogie, B. (2008) Sustained complete remission in multiple myeloma linked to bortezomib in total therapy 3: comparison to total therapy 2. British Journal of Haematology, 140, 625 634.
8. Richardson, P., Chanan-Khan, A., Lonial, S., Krishman, A., Carroll, M., Cropp, G.F., Kersey, K., Abitar, M., Johnson, R.G., Hannah, A.L. Anderson, K. (2007) Tanespimycin (T) + bortezomib (BZ) in multiple myeloma (MM): confirmation of the recommended dose using a novel formulation. Blood (ASH Meeting Abstracts), 110, Abstract 1165.
9. San Miguel, J., Schlag, R., Khuagena, N., Dimopoulos, M.A., Shpilberg, O., Kropff, M., Spicka, I., Petrucci, M.T., Palumbo, A.l., Samoilova, O.S., Dmoszynska, A., Abdulkadyrov, K.M., Schots, R., Jiang, B., Mateos, M.V., Anderson, K.C., Esseltine, D.L., Liu, K., Cakana, A., van de Velde, H. Richardson, P.G. (2008) Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. New England Journal of Medicine, 359, 906 917.
10. Shaughnessy, J., Zhan, F., Burington, B., Huang, Y., Colla, S., Hanamura, I., Stewart, J.P., Kordesmeier, B., Randolph, C., Williams, D.R., Xiao, Y., Xu, H., Epstein, J., Anaissie, E., Krishna, S., Cottler-Fox, M., Hollmig, K., Mohiuddin, A., Pineda-Roman, M., Tricot, G., van Rhee, F., Sawyer, J., Alsayed, Y., Walker, R., Zangari, M., Crowley, J. Barlogie, B. (2007) A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood, 109, 2276 2284.
11. Terpos, E., Kastritis, E., Roussou, M., Heath, D., Christoulas, D., Anagnostopoulos, N., Eleftherakis-Papaiakovou, E., Tsionos, K., Croucher, P. Dimopoulos, M.A. (2008) The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis. Leukemia, 22, 2247 2256.
12. Zhan, F., Huang, Y., Colla, S., Stewart, J.P., Hanamura, I., Gupta, S., Epstein, J., Yaccoby, S., Sawyer, J., Burington, B., Anaissie, E., Hollmig, K., Pineda-Roman, M., Tricot, G., van Rhee, F., Walker, R., Zangari, M., Crowley, J., Barlogie, B. Shaughnessy, Jr., J. (2006) The molecular classification of multiple myeloma. Blood, 108, 2020 2028.